Havas Health, part of Havas Group, and Vencore have formed HVH Patient Precision Analytics, an entity that will leverage analytics and predictive modeling with deep therapeutic area expertise that will provide data and insights into the rare and niche disease market.
As part of the new venture, HVH is now launching its first service offering to enable biopharma commercial leaders to find undiagnosed patients with a rare disease. By leveraging large amounts of disparate health data, HVH collects, aggregates and analyzes the journeys of known patients, helping to inform early diagnosis and intervention of undiagnosed patients at the MSA, Zip code or physician level.
The joint venture will be led by Steve Costalas from Vencore, who will serve as CEO, and Jeff Ceitlin from Havas Health, who will serve as chief commercial officer.
“This joint venture gives our proven defense-grade patient finder technology increased breadth and scale to better serve the pharmaceutical industry,” Costalas said. “Our potentially life-saving analytical tools will assist the earlier identification and diagnosis of disease in patients across the country.”
Related: Vencore Labs Receives $5M Award for DARPA RadioMap Program
